Canterbury, United Kingdom

Karl Richard Gibson


Average Co-Inventor Count = 7.2

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Bishop's Stortford, GB (2002)
  • Canterbury, GB (2008)

Company Filing History:


Years Active: 2002-2008

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovations of Karl Richard Gibson

Introduction

Karl Richard Gibson is a notable inventor based in Canterbury, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target neurological disorders. With a total of 2 patents, Gibson's work is focused on innovative solutions for serious health issues.

Latest Patents

Gibson's latest patents include groundbreaking research on cyclohexyl sulphones as gamma-secretase inhibitors. These compounds are designed to inhibit gamma-secretase, which can be instrumental in the treatment or prevention of Alzheimer's disease. Another significant patent involves triazolo-pyrimidine as ligands for GABA receptors. These substituted or 6,7-ring fused 1,2,3-triazolo[1,5-a]pyrimidine derivatives serve as selective ligands for GABA receptors, offering potential therapeutic benefits for disorders of the central nervous system, including anxiety and convulsions.

Career Highlights

Gibson is currently associated with Merck Sharp & Dohme Corporation, a leading global healthcare company. His work at Merck has allowed him to focus on innovative drug development, contributing to advancements in medical science.

Collaborations

Throughout his career, Gibson has collaborated with esteemed colleagues such as Howard Barff Broughton and Jose Luis Castro Pineiro. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Karl Richard Gibson's contributions to the field of pharmaceuticals through his innovative patents highlight his commitment to addressing critical health challenges. His work continues to pave the way for advancements in treatments for neurological disorders.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…